Table 5.

Monitoring treatment in FH children and adolescents

Hepatic aminotransferases, creatine kinase (CK) and creatinine levels should be measured before starting treatment. After starting treatment, lipid levels, weight, growth, physical and sexual development, and hepatic aminotransferases should be monitored. Hepatic aminotransferases should be monitored at least every 3 months if there is a history of liver disease, or more frequently if levels rise to 3-fold greater than the upper limit of normal; bilirubin may be used to gauge liver toxicity. Plasma CK levels should be measured if musculoskeletal symptoms are reported. Fasting plasma glucose and/or random glycated haemoglobin should be measured every 6 months in children on higher doses of statins who are obese or have impaired glucose tolerance.